Wockhardt sets issue price at Rs 225 per share for Rs 748-cr rights issue
The issue price has been fixed at Rs 225 per fully paid-up equity share, including a premium of Rs 220 per share.
New Delhi: Pharmaceuticals firm Wockhardt Ltd on March 3 said it has fixed the issue price at Rs 225 per share for its Rs 748-crore rights issue. The capital raising committee of the company's board on March 3 decided to approve the issue of 3.33 crore fully paid-up equity shares, aggregating to a little over Rs 748 crore, Wockhardt said in a regulatory filing.
The issue price has been fixed at Rs 225 per fully paid-up equity share, including a premium of Rs 220 per share, it added. The issue will open on March 15 and close on March 22, 2022.
Earlier in January this year, Wockhardt's board had approved raising up to Rs 1,000 crore through a rights issue to its existing shareholders. The objective of the issue is to meet the financing needs of the company for repayment of subordinated debt, financing research and development initiatives and for general corporate purposes, it said.
Read Also - Wockhardt net profit jumps over 11-fold to Rs 37.17 crore in Q2
Wockhardt is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India's leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce globally. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines.
Read Also - Wockhardt hosts Prince Charles at its Wrexham facility in UK
The company has successfully created an integrated multi-technology capability to manufacture all types of dosage forms including sterile injectables and lyophilised products. Highly skilled technicians operate 12 manufacturing facilities that are US FDA, UK MHRA and EMEA compliant sites in India, the US and Europe.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.